Partners Jeanne Gills and Jeff Costakos were quoted in a Bloomberg Law article, “Patent Filings, Litigation May Shift in Economic Crisis,” about the effect the economic shutdown caused by the coronavirus is expected to have on patent applications and enforcement actions.
Gills, vice chair of the firm’s national intellectual property department, said some companies might be sensitive to the financial commitment of patent litigation, weighing whether this is “a good use of money or should we be using our resources, using our legal team, to help us do something else.”
Costakos, who chairs the firm’s IP litigation practice, said some companies might have no choice but to file suit now. But those that can wait might want to see how the competitive environment shakes out. “The things that might have motivated you to file a lawsuit today might be different six months from now,” he said. “Who knows what companies are still going to be around, or what their competitive situations are going to be.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”